AMGN AMGEN Inc.

$AMGN should help the $IBB cohort Monday. AI long term will benefit the biotech sector w/discovery and regulatory admin etc it's going to finally give tech ETF's something to compete with. $QQQ

$AMGN I bought this stock a few years back when my niece started working there. I figured if they were smart enough to hire her, the company would do alright. And they have.

$AMGN installed David W. Gibbs to its Board, where he'll serve on the Audit and Compensation & Management Development committees.

$AMGN: unnamed in Humphreys: Amgen said patient health data sat in third-party cloud environments, but has not named the providers or how they were reached. Plaintiffs allege inadequate controls. Nothing to claim. Open Class Actions.

$AMGN: A potential breakthrough in aggressive lung cancer—and a major growth opportunity. Amgen’s IMDELLTRA, combined with AstraZeneca’s $AZN IMFINZI, cut the risk of death by 58% in a Phase 3 trial of patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months vs. 12.7 months with IMFINZI alone—an 8.4-month improvement. Nearly 80% of patients receiving the combination were alive at one year, vs. 53% on IMFINZI alone. (Source: CNBC)

$AMGN: still no headcount in Humphreys. Amgen has not said how many patients were hit in the July cloud breach, and notice letters had not gone out. Plaintiffs allege patient health data was taken. Nothing to claim. Open Class Actions.

$AMGN demonstrated strong Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with ~68% histologic remission at week 24.

$AMGN It is time we started treating AMGN as an unusual combination of highly financially disciplined, shareholder friendly and mature pharma company & a highly competitive, innovative biotech with multibagger growth engines coming to fruition. They deserve a premium multiple. Whatever happens with data centres, this company is still going to be growing and innovating in 10 years time, as well as in the coming quarters.

$AMGN: six days is the tell in Humphreys. Amgen disclosed the July cloud breach in a July 31 SEC filing, and the proposed class action landed Aug. 6 in C.D. Cal., No. 2:26-cv-08688. No class certified, nothing to claim. Open Class Actions.

$AMGN IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER "Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine"

$AMGN 🏥 Amgen announced real-world study results showing Repatha reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in over 544,000 adults with atherosclerotic cardiovascular disease and prior statin use followed for up to four years. Prioritized by relevance

$AMGN Excellent earnings! The stock is still sitting comfortably at around fair (conservative / strict) value. But for speculative value and growth quality, it should be much higher perhaps.

$AMGN going into a top chart kind of says this will go down I mean, I don’t know how far but I think the lowest it’ll go is 410 PE is a little bit high. I don’t know. I got one put at 4:10 so I’m a little biased.

$AMGN Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer https://www.cnbc.com/2026/10/24/amgen-imdelltra-lung-cancer-data.html?__source=iosappshare%7Ccom.google.chrome.ios.OpenExtension

$AMGN · $AZN 🏥 Amgen announced interim Phase 3 DeLLphi-305 results showing IMDELLTRA plus AstraZeneca's IMFINZI reduced the risk of death by 58% versus IMFINZI alone in first-line extensive-stage small cell lung cancer, with nearly 80% of patients alive at one year versus 53%. Selected from hundreds of headlines

$AMGN Bullish energy. Price holding up well in volatile times, with genuine pipeline excitment, on top of solid earnings. Easily will be over 500 within 3-6 months.

$AMGN Q3 '26 revenue rose 8% YoY to $10.4B, with six growth drivers +27% (>70% of sales). Non-GAAP operating margin was 47%; 17 products annualize above $1B. Repatha new prescriptions +60%, TEZSPIRE +15% vs market +3%. No formal FY'27 guidance disclosed. Catalysts in play - IMDELLTRA Phase III median survival 21.1 vs 12.7 months; filings underway. - MariTide Phase III fully enrolled; 2027 readouts expected. - Dazodalibep positive Phase III data; another readout due Q4. - Repatha revenue +37% YoY; primary prevention opportunity expands. - UPLIZNA +191% to $451M; 25 ex-US launches planned. - TEZSPIRE and IMDELLTRA bolster pipeline. Risks to watch - TEPEZZA sales declined 6% YoY amid inventory comparison. - MariTide tolerability and obesity market viability unproven. - Dazodalibep symptomatic study and regulatory pathway uncertain. - Biosimilar OPDIVO/KEYTRUDA face newer subcutaneous rivals. - ~$2.6B FY26 capex for manufacturing creates scale-up risk. - Biosimilar launch timelines remain undisclosed.

$AMGN announced a real-world study showing Repatha cut fatal or non-fatal heart attacks by 20% versus ezetimibe.

$AMGN Q3 net income was 3,864 million dollars, and an unrealized gain of 1.5 billion dollars on the BeOne stake sits inside other income for the quarter. The 10-Q investment note puts that stake at about 17 percent, valued at 6.9 billion dollars at September 30, and sales are capped at 5 percent of BeOne shares outstanding in any rolling 12 months.

$AMGN reported earnings after the close yesterday. Adjusted EPS beat estimates: $6.45 vs. $5.79 expected, according to Stock Meadow.